CD38 and acute myeloid leukemia: Due to this large heterogeneity and to minimize the need to use the above mentioned secondary gating parameters, we designed an LSC tube that includes a broad panel of different markers (Table 2) that enables specific detection and accurate assessment of the frequency of CD34+CD38− LSCs in the majority of AML cases (Zeijlemaker et al., 2016b).